This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Boehringer Ingelheim & Enara Bio enter Strategic Collaboration & Licensing Agreement to discover novel shared antigens for cancer immunotherapies

Boehringer Ingelheim & Enara Bio enter Strategic Collaboration & Licensing Agreement to discover novel shared antigens for cancer immunotherapies

12 Jan 2021

Ingelheim, Germany and Oxford and London, UK, January 12th, 2021 – Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform. This new collaboration combines Boehringer Ingelheim’s approach to tackle cancer through pairing leading science with... Read more

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins

12 Jan 2021

Novel self-labelling mammalian display method for identifying antibodies against membrane proteins in their native configuration Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development 12 January 2021, Oxford, UK: OXGENE™, a biotechnology company offering integrated discovery and manufacturing... Read more

Immunocore announces closing of $75.0 Million Series C round

Immunocore announces closing of $75.0 Million Series C round

11 Jan 2021

Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 January 2021) Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune... Read more

Exscientia launches Miami Office to recruit US-based Technology talent as part of continued expansion

Exscientia launches Miami Office to recruit US-based Technology talent as part of continued expansion

04 Jan 2021

Exscientia, the world-leading artificial intelligence (AI) driven Pharmatech company, today announces the opening of its US based Miami office, with recruitment starting immediately. Led by Chief Research Engineer, Adrian Schreyer, Exscientia are recruiting both AI Engineers and Cheminformaticians to join the new Miami office. Members of the team will have extensive opportunities to work in the globally important field of... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More